ethyl 3(4-chlorophenyl)-2-(6-chloroindol-N-yl)propanoate | 848983-40-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 3(4-chlorophenyl)-2-(6-chloroindol-N-yl)propanoate
• 英文别名: Ethyl 2-(6-chloroindol-1-yl)-3-(4-chlorophenyl)propanoate
• CAS: 848983-40-4
• 化学式: C₁₉H₁₇Cl₂NO₂
• 分子量: 362.255
• InChiKey: CJOPMDRXMBCVIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  31.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Substituted sulfonamides
  申请人：Armstrong M. Helen

  公开号：US20070105914A1

  公开（公告）日：2007-05-10

  The substituted sulfonamides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  本发明中的替代磺胺类化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，并可用于治疗、预防和抑制由CB1受体介导的疾病。本发明中的化合物可用作中枢作用药物，治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病（包括多发性硬化症和格林-巴利综合征）、病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍，以及哮喘、便秘、慢性肠假性梗阻和肝硬化的治疗。
• EP1663113A4
  申请人：——

  公开号：EP1663113A4

  公开（公告）日：2007-06-13
• SUBSTITUTED SULFONAMIDES
  申请人：Merck & Co., Inc.

  公开号：EP1663113A2

  公开（公告）日：2006-06-07
• [EN] SUBSTITUTED SULFONAMIDES<br/>[FR] SULFONAMIDES SUBSTITUES
  申请人：MERCK & CO INC

  公开号：WO2005027837A2

  公开（公告）日：2005-03-31

  The substituted sulfonamides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson’s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.